CD8A and non-small cell lung carcinoma: Patients with recurrent/metastatic (R/M) thymic epithelial tumours (n = 31) or metastatic NSCLC (n = 33 in discovery set and n = 46 in validation) with a ≥2.8‐fold increase of CD8+ Ki67+ T cells 1 week after first treatment compared to baseline had improved response and disease control, longer PFS, and/or longer OS.52